Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

Tumor hypoxia causes resistance to radiation and chemotherapy. Evofosfamide (TH‐302) has exhibited specific hypoxia‐dependent cytotoxicity against primary acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) samples in vitro. Based on these findings, a Phase I study of evofosfamide was designed for patients with relapsed/refractory leukemia (NCT01149915). In this open‐label study, patients were treated with evofosfamide as a 30–60 min/day infusion on Days 1–5 of a 21–day cycle (Arm A, n = 38) or as a continuous infusion over 120 hr over Days 1–5 of a 21‐day cycle (Arm B, n = 11). Forty‐nine patients were treated including 39 (80%) with AML and 9 (18%) with ALL. Patients had received a median of five prior therapies. In Arm A, the dose‐limiting toxicities (DLTs) were grade 3 esophagitis, observed at a dose of 550 mg/m2. The maximum tolerated dose (MTD) was a daily dose of 460 mg/m2. In Arm B, the DLTs were grade 3 stomatitis and hyperbilirubinemia, observed at a daily dose of 460 mg/m2. The continuous infusion MTD was a daily dose of 330 mg/m2. Hypoxia markers HIF‐1α and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy. The combined overall response rate in Arms A and B was 6% (2 CR/CRi and 1 PR), with all responses seen in Arm A. Evofosfamide has shown limited activity in heavily pretreated leukemia patients. Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted. Am. J. Hematol. 91:800–805, 2016. © 2016 Wiley Periodicals, Inc.

[1]  J. Velez,et al.  Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models , 2015, Clinical Cancer Research.

[2]  M. Borad,et al.  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Ganjoo,et al.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Wetzler,et al.  Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models , 2013, Clinical Cancer Research.

[5]  J. Laubach,et al.  Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma. , 2013 .

[6]  M. Konopleva,et al.  Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment , 2012, Cancer biology & therapy.

[7]  Damien J. Ferraro,et al.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules , 2012, Cancer Chemotherapy and Pharmacology.

[8]  Kyeong Lee,et al.  Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. , 2012, European journal of medicinal chemistry.

[9]  E. Ebert,et al.  Gastrointestinal manifestations of leukemia , 2012, Journal of gastroenterology and hepatology.

[10]  Charles P. Lin,et al.  Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. , 2011, Blood.

[11]  D. Campana,et al.  Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104 , 2011, PloS one.

[12]  W. Wilson,et al.  Targeting hypoxia in cancer therapy , 2011, Nature Reviews Cancer.

[13]  K. Ganjoo,et al.  A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma , 2011, Oncology.

[14]  P. Starostik,et al.  Hypoxia-inducible factor-1α protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. , 2011, Leukemia research.

[15]  Suzanne F. Jones,et al.  Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies , 2011, Clinical Cancer Research.

[16]  C. Hart,et al.  Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. , 2010, Blood.

[17]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[18]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[19]  Jun O. Liu,et al.  Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells , 2009, Proceedings of the National Academy of Sciences.

[20]  P. Jones,et al.  Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study , 2008, Clinical Cancer Research.

[21]  Rachelle S. Singleton,et al.  Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104 , 2007, Clinical Cancer Research.

[22]  M. Davila.  Neutropenic enterocolitis: Current issues in diagnosis and management , 2007, Current infectious disease reports.

[23]  R. Boyle,et al.  Hypoxia: targeting the tumour. , 2006, Anti-cancer agents in medicinal chemistry.

[24]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Sauerbruch,et al.  Neutropenic enterocolitis in adults: systematic analysis of evidence quality , 2005, European journal of haematology.

[26]  Y. Pommier,et al.  Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1 , 2004, Cancer Research.

[27]  C. Lottaz,et al.  Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF , 2004, Leukemia.

[28]  S. Kaufmann,et al.  Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. , 2002, Mayo Clinic proceedings.

[29]  P. Iversen,et al.  Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats , 2000, Cell proliferation.

[30]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[31]  C. Coleman,et al.  Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. , 1999, International journal of radiation oncology, biology, physics.

[32]  Durand Re.  The influence of microenvironmental factors during cancer therapy. , 1994 .

[33]  R. Durand.  The influence of microenvironmental factors during cancer therapy. , 1994, In vivo.

[34]  L. H. Gray,et al.  The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. , 1953, The British journal of radiology.